Capsule Endoscopy for HEmorrhage in the ER (CHEER)
Primary Purpose
Upper Gastrointestinal Bleeding
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PillCam UGI
Standard of Care
Sponsored by
About this trial
This is an interventional diagnostic trial for Upper Gastrointestinal Bleeding focused on measuring capsule endoscopy, PillCam, upper Endoscopy, emergency Department, upper gastrointestinal bleeding, GI bleed
Eligibility Criteria
Inclusion Criteria:
- Individuals aged 18 years or older presenting to the Emergency Department with acute overt UGIB, defined as bloody emesis and/or coffee ground vomiting and/or melena within the previous 48 hours.
Exclusion Criteria:
- Stable for discharge without further testing (Glasgow Blatchford Score of 0
- Upper GI bleed with hemodynamic shock (BP <90mmHg and pulse > 120 beats per minute)
- Active hematemesis
- High- Risk Upper GI Bleed (Glasgow Blatchford Score greater than or equal to 6)
- Known history of gastric cancer
- Known history of gastric or esophageal varices
- GI surgery within the last 6 months
- Dysphagia, swallowing disorder, Zencker' s diverticulum, suspected bowel obstruction or perforation.
- Gastroparesis, Gastric outlet obstruction, Crohn's disease, past UGI tract surgery
- Pregnancy/ lactation
- Altered mental status (e.g., hepatic encephalopathy) that limits the ability to swallow a capsule
- Expected to have Magnetic Resonance Imaging examination within 7 days
- On medications that may coat the upper GI tract such as antacids or sucralfate or Maalox.
- Patient either refuses or is unable to get traditional EGD.
- Patient does not have reliable contact information - no phone, no permanent address.
- Patient refuses
- Unable to provide written consent
- Prisoner
- Non-English Speaker
- Suspected small bowel or lower GI Bleeding
- Unable to follow up with confirmatory EGD.
Sites / Locations
- George Washington University
- Duke University School of Medicine
- Temple University
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Active Control
Experimental
Arm Description
Video Capsule Endoscopy will be administered during ED, but video will not be read until after inpatient EGD. Subject will have hospital admission with an EGD conducted during hospital stay.
Subject will have Video Capsule Endoscopy read during ED length of stay, disposition will be determined using Capsule Endoscopy Risk Assessment.
Outcomes
Primary Outcome Measures
Number of Participants Discharged for Outpatient Management of Upper GI Bleeds
Our primary goal is to determine whether ED VCE is able to discharge low risk patients for outpatient management of upper GI bleeds.
Secondary Outcome Measures
Detection Rate of Video Capsule Endoscopy
Our secondary objective is to present the prevalence of clinical findings in VCE subjects based on gastroenterologist interpretation.
Full Information
NCT ID
NCT03458000
First Posted
March 1, 2018
Last Updated
May 4, 2023
Sponsor
George Washington University
Collaborators
Medtronic
1. Study Identification
Unique Protocol Identification Number
NCT03458000
Brief Title
Capsule Endoscopy for HEmorrhage in the ER
Acronym
CHEER
Official Title
Capsule Endoscopy for Hemorrhage in the ER
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
April 17, 2018 (Actual)
Primary Completion Date
March 15, 2020 (Actual)
Study Completion Date
September 7, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
George Washington University
Collaborators
Medtronic
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a multi-center randomized controlled trial examining the use of Video Capsule Endoscopy (VCE) to discharge low-moderate risk patients with suspected upper gastrointestinal bleeds (UGIB) from the Emergency Department (ED.) The investigators will enroll 100 subjects at 4 sites who present with signs of hemodynamically stable UGIBs and compare VCE risk assessment to an Active Control (AC) group who receive inpatient upper endoscopy (EGD).
Detailed Description
Video capsule endoscopy (VCE) was initially approved in 2001 by the Food and Drug Administration. VCE offers potential advantages over traditional EGD including the ability to be performed 24 hours a day without sedation and interpreted at the bedside by emergency physicians. In addition, VCE is much less invasive, is painless, and enables the patient to pursue normal daily activities after the procedure.
Our primary goal is to test whether ED Video Capsule Endoscopy (VCE) is able to safely discharge low risk patients for outpatient evaluation and management. Our secondary objective is to estimate the sensitivity and specificity of VCE compared to subsequent EGD in the detection of serious bleeding lesions in the upper gastrointestinal (GI) tract.
Research Coordinator will screen potential patients with signs of upper GI bleeding. Patients who screen as eligible will be approached about potential interest, to review of inclusion and exclusion criteria, and obtain informed consent. Research Coordinator will calculate traditional risk stratification scores and once enrolled, all subjects will be randomized to either Active Control (AC) [admission plus EGD within hospital stay] or experimental Capsule Endoscopy Risk Assessment (CERA) in ED. Only patients randomized to the experimental arm will receive video capsule endoscopy in the emergency department.Within 2 hours of presenting to the ED, patient will ingest video capsule-- RC will monitor progress on real-time viewer for passage through pylorus. Upon passing the pylorus, we will record 5 more minutes of video or until battery runs out - whichever occurs first. Patient data will be completed using a standardized data collection tool including the following elements: chief complaint of patient, history of present illness, past medical history, pertinent lab findings, current medications, vital signs, focused physical exam findings and all relevant treatments administered during the ED and hospital stay.
For Active Control (AC) group each patient will be admitted. During hospital admission, EGD will be performed on all subjects and hemostasis therapy applied as necessary. The study team decided against mandating that EGD be performed within 24 hours of hospital admission.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Upper Gastrointestinal Bleeding
Keywords
capsule endoscopy, PillCam, upper Endoscopy, emergency Department, upper gastrointestinal bleeding, GI bleed
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Active Control
Arm Type
Active Comparator
Arm Description
Video Capsule Endoscopy will be administered during ED, but video will not be read until after inpatient EGD. Subject will have hospital admission with an EGD conducted during hospital stay.
Arm Title
Experimental
Arm Type
Experimental
Arm Description
Subject will have Video Capsule Endoscopy read during ED length of stay, disposition will be determined using Capsule Endoscopy Risk Assessment.
Intervention Type
Device
Intervention Name(s)
PillCam UGI
Intervention Description
An esophageal capsule endoscope which is designed to visualize the upper gastrointestinal tract.
Intervention Type
Other
Intervention Name(s)
Standard of Care
Other Intervention Name(s)
SOC
Intervention Description
Patient was admitted to hospital for care and received in-patient EGD.
Primary Outcome Measure Information:
Title
Number of Participants Discharged for Outpatient Management of Upper GI Bleeds
Description
Our primary goal is to determine whether ED VCE is able to discharge low risk patients for outpatient management of upper GI bleeds.
Time Frame
30 Days
Secondary Outcome Measure Information:
Title
Detection Rate of Video Capsule Endoscopy
Description
Our secondary objective is to present the prevalence of clinical findings in VCE subjects based on gastroenterologist interpretation.
Time Frame
30 Days
Other Pre-specified Outcome Measures:
Title
Patient Satisfaction With VCE Procedure
Time Frame
30 Days
Title
GI Physician Final Read and Site Physician Agreement on VCE Results
Time Frame
30 Days
Title
Number of Participants With Serious Adverse Events at Day 7 and Day 30
Description
Assess for mortality, re-bleeding, total blood transfusions, surgery (capsule-specific group)
Time Frame
30 Days
Title
ED Length of Stay
Time Frame
30 Days
Title
Hospital Length of Stay
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
1. Individuals aged ≥ 18 years presenting to the Emergency Department with likely upper GI bleed (bloody emesis and/or coffee ground vomiting and/or melena) that has occurred within the previous 48 hours.
Exclusion Criteria:
Upper GI Bleed with hemodynamic instability (BP<90 mmHg, pulse>120 beats per minute, and Hgb < 9 g/dL)
High Risk Upper GI Bleed (Glasgow Blatchford Score* ≥ 6)
Signs, symptoms or history of liver cirrhosis or liver failure
Signs, symptoms or history of decompensated heart failure or congestive heart failure
Presumed Pregnant, trying to conceive or breastfeeding
Known history of gastric cancer
Known history of gastric or esophageal varices
GI surgery within the last 6 months
Prior enrollment in the CHEER Study
Prisoner or Ward of State
Trouble swallowing, suspected bowel obstruction or perforation, per treating clinician
Past UGI tract surgery (e.g., Bilroth I or II, esophagectomy, gastrectomy, bariatric procedure) that changes Gastrointestinal anatomy
Known history of gastroparesis, esophageal stricture or Crohn's disease
Altered mental status that limits the ability to swallow a capsule
Expected to have Magnetic Resonance Imaging (MRI) examination within 7 days
Consumed medications within the past 12 hours that may coat the upper GI tract such as antacids or sucralfate or Maalox and potentially limits capsule visualization
Patient either refuses or is unable to get traditional EGD
Patient does not have reliable contact information - no phone, no permanent address
Patient refuses
Unable to provide written consent
Non-English speaker
Suspected middle or lower GI bleeding
Treating ED Physician is not amenable to admission or discharge based on randomization or Video Capsule Endoscopy results. * As a modification, the GBS Score modified from the traditional GBS score to reduce the Hemoglobin cut-off for 6 points from 10g/dL to 9 g/dL (see Appendix B, CHEER 4; patient screening)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Meltzer, MD
Organizational Affiliation
George Washington University- Department of Emergency Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
George Washington University
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20037
Country
United States
Facility Name
Duke University School of Medicine
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Temple University
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19140
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
23398660
Citation
Meltzer AC, Ali MA, Kresiberg RB, Patel G, Smith JP, Pines JM, Fleischer DE. Video capsule endoscopy in the emergency department: a prospective study of acute upper gastrointestinal hemorrhage. Ann Emerg Med. 2013 Apr;61(4):438-443.e1. doi: 10.1016/j.annemergmed.2012.11.008.
Results Reference
derived
Learn more about this trial
Capsule Endoscopy for HEmorrhage in the ER
We'll reach out to this number within 24 hrs